Integrated Diagnostics : EGM 2024 - Summary of Proxy Voting
June 12, 2024 at 11:12 am EDT
Share
EXTRAORDINARY GENERAL MEETING
12 JUNE 2024
SUMMARY OF PROXY VOTING
VOTES FOR
%
VOTES
%
VOTES
TOTAL
AGAINST
WITHHELD
SHARES
VOTED
Passed as Special Resolutions:
1. THAT, subject to the
other resolutions, the
Company is hereby
authorised to delist
voluntarily the
Company's Equity
Securities from the
EGX (see notice of
EGM)
468,661,883
93.43%
32,944,387
6.57%
6,583
501,612,853
2. THAT, subject to the
other resolutions, the
Company is hereby
authorised to make
market purchases of a
maximum of
30,104,435 Equity
Securities,
representing up to
approximately 5.02%
of the sum of the total
issued ordinary share
capital of the Company
at a price (exclusive of
expenses) amounting
to 18.62 Egyptian
pounds per Equity
Security (see notice of
EGM)
468,661,883
93.43%
32,938,830
6.57%
12,140
501,612,853
Passed as Ordinary Resolutions:
3. THAT, subject to the other resolutions, the Company is hereby authorised to hold the Equity Securities purchased as treasury shares (see notice of EGM)
468,661,883
93.43%
32,944,387
6.57%
6,583
501,612,853
4. THAT, subject to the other resolutions, the Company is hereby authorised to execute and deliver any documents in connection with the Company holding, as treasury shares, the Equity Securities purchased (see notice of EGM)
468,661,883
93.43%
32,938,830
6.57%
12,140
501,612,853
Attachments
Original Link
Original Document
Permalink
Disclaimer
IDH - Integrated Diagnostics Holdings plc published this content on
12 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
12 June 2024 15:10:04 UTC.
Integrated Diagnostics Holdings PLC is a consumer healthcare company. The Company operates in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Company is engaged in offering services in immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, histopathology, genetics, radiology and others. The Companyâs brands include Al Borg Scan, Al Mokhtabar, Ultralab, Biolab, Echo-Lab and others. It operates in approximately 552 branches. It offers more than 3,000 diagnostics tests ranging from routine to advanced. Its common tests include those for cholesterol, diabetes, pregnancy and substance abuse. Through Al Borg Scan, it offers a full range of radiology services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography-computed tomography (PET-CT), electromyography (EMG), electrocardiogram (ECG), electroencephalogram (EEG), ultrasound, x-ray, mammograms and cath lab facilities.